3
SEEO

SEEO

JULIO 2020 N° 2 Volumen 3

Oncology Patients Quality Of Life Regarding Anti-Egfr Induced Cutaneous Toxicity At Burgos University Hospital

Section: Original

Authors

Laura Calvo

Contact email: lauracgar@hotmail.es

Keywords:

Quality of life; Receptor; Epidermal Growth Factor; Toxicity; AntibodiesMonoclonal

Versión en Español

Título:

Efectos de la toxicidad cutánea inducida por el tratamiento anti-egfr en la calidad de vida de los pacientes del hospital de día oncológico del Hospital Universitario de Burgos

Artículo completo no disponible en este idioma / Full article is not available in this language

Bibliography

  1. Dalmases A, Rojo F, Rovira A, Albanell J. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm]. Med Clin (Barc) [Internet]. 2013;141(4):176–80.
  2. Esquirol Caussa J HVE. Factor de Crecimiento Epidérmico (EGF): Innovación y Seguridad. Med Clin (Barc) [Internet]. 2014;1–8.
  3. Achell L, Hierro S, Maya I. Manejo y prevención de efectos secundarios al empleo de un anticuerpo monoclonal inhibidor de la señal de los receptores del factor de crecimiento epidérmico. Gac Mex Oncol [Internet]. 2016;15(1):31–39.
  4. Tischer B, Huber R, Kraemer M, Lacouture ME. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Supportive Care Cancer [Internet]. 2017;25(2):651–60.
  5. Chanprapaph K, Vachiramon V, Rattanakaemakorn P. Epidermal growth factor receptor inhibitors: A review of cutaneous adverse events and management. Dermatol Res Pract [Internet]. 2014;2014.
  6. Leporini C. Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review. J Physiol Pharm Pharmacol. 2011;1(1):35–9.
  7. Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010;116(16):3916–23.
  8. Holcmann M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol [Internet]. 2015;2(4): e1004969.
  9. Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: A questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–33.
  10. Developed D. Guidelines - Prevention and treatment of rash in patients treated. 2012;1–16.
  11. Schwartzmann L. Health-related quality of life: conceptual aspects. 2003;(2):9–21.
  12. Wagner LI, Berg SR, Hlubocky FJ, Aneja M, Cella D, Lacouture ME. Lynne I. Wagner, Sara R. Berg, Mona Gandhi, Fay J. Hlubocky, Kimberly Webster, Monika Aneja, David Cella & Mario E. Lacouture. Dev a Funct Assess Cancer Ther Quest to assess dermatologic symptoms Assoc with epidermal growth factor Recept Inhib [Internet]. 2013;21(4):1033–41.
  13. Protección de Datos de Carácter Personal. Ley orgánica 15/1999, de 13 de diciembre. Boletín Oficial del Estado, nº 298, p. 43088-43099.
  14. Chan A, Cameron MC, Garden B, Boers-Doets CB, Schindler K, Epstein JB, et al. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Support Care Cancer. 2016;23(8):2231-44.
  15. Chren MM. The Skindex Instruments to Measure the Effects of Skin Disease on Quality of Life. Dermatol Clin [Internet]. 2013;30(2):231–6.
  16. Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, et al. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer [Internet]. 2012;1–10.
  17. Andreis F, Rizzi A, Mosconi P, Braun C, Rota L, Meriggi F, et al. Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes [Internet]. 2010;1–7.
  18. Lacouture ME, Mitchell EP, Piperdi B, Pillai M V, Shearer H, Iannotti N, et al. Skin Toxicity Evaluation Protocol with Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients with Metastatic Colorectal Cancer. J Clin Oncol [Internet]. 2010 Mar 10;28(8):1351–7.
  19. Hofheinz RD, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, et al. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. The Oncologist. 2016; 21:1483–91.
  20. Sinclair R. Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors. Asia Pac J Clin Oncol. 2014;10(1):11–7.

Mandala M, Massi D, De Giorgio V. Cutaneous toxicities of BRAF inhibitors clinical and pathological challenges and call to action. Oncol Hematol [Internet]. 2013;88(2):318–37.